Interferon (IFN) and meta-iodobenzylguanidin (MIBG) are active in metastatic carcinoids. In a phase II study, we evaluated the effect upon diagnostic 131I-MIBG uptake and the clinical response of the combination. 131I-MIBG scintigraphy was performed prior to treatment, after 8 weeks of IFN and after unlabelled MIBG. The tumour over non-tumour (T/NT) ratios were quantitatively determined by comp...

This study measured the growth over time of experimental coronary artery (CA) thrombi by radiolabeled fibrinogen uptake. 125I-fibrinogen was injected into dogs and 24 hours later CA thrombi were induced by electrical current. Twenty-four hours after CA thrombus induction, 131I-albumin (group A) or 131I-fibrinogen (group B) was injected. At 48 hours after thrombi induction, the thrombi were remo...

Introduction In order to discharge the patients receiving treatment with large radiation doses of 131I for thyroid cancer, it is necessary to measure and evaluate the external dose rates of these patients. The aim of the study was to assess a new method of external dose rate measurement, and to analyze the obtained results as a function of time. Materials and Methods In this study, a telescopic...

A T4 suppression test involving 24-h thyroidal 131I uptake was carried out on patients with Graves' disease during therapy with an antithyroid drug. Thirty-three patients received propylthiouracil (PTU) for at least 1 year. Each patient was given 75 micrograms L-T3 daily for 8 days in conjunction with PTU (50 mg/day) at the time of the experiment and then the 24-h thyroidal 131I uptake (post T3...

In antibody-directed enzyme-prodrug therapy (ADEPT), an antibody-bound enzyme localizes to tumor tissue, where it selectively converts a subsequently administered non-toxic prodrug into a cytotoxic drug. A33scFv::CDy is a bifunctional fusion construct comprising a single chain antibody against the gpA33 antigen and the prodrug-converting enzyme cytosine deaminase. gpA33 is highly and homogeneou...

Toll-like receptor 5 (TLR5) is overexpressed in several cancers and metastases, and presents an enticing target for molecular imaging of primary tumors. In the present study, 131I-anti-TLR5 monoclonal antibody (mAb) was evaluated for its use as a novel radiotracer for imaging hepatocarcinoma in mice bearing H22 tumors. The expression of TLR5 was analyzed by quantitative polymerase chain reactio...

BACKGROUND Both tumor cells and their supporting endothelial cells should be considered for targeted cell killing when designing cancer treatments. Here we investigated the feasibility of combining radioiodide and antiangiogenic therapies after baculovirus-mediated transfer of genes encoding the sodium iodide symporter (NIS) and plasminogen kringle 5 (K5). METHODS A recombinant baculovirus co...

A wide spectrum of potentially misleading artefacts can arise in 131I whole body scans from various anatomical variants and physiological processes as well as several unrelated non-thyroidal disease processes. A proper understanding of the causes of false positive 131I scans is essential for accurate interpretation of the images and to obviate diagnostic errors which may lead to administration ...

33 patients with advanced malignant melanoma were studied after intravenous administration of 131I-labeled Fab fragments specific for p97, an oncofetal glycoprotein of human melanoma. In all, 47 gamma camera imaging studies were performed for the purpose of localization of metastatic deposits. In addition to tumor, 131I-Fab uptake was also seen in liver and kidney. 20 of these studies included ...

Detection of residual tissue after thyroidectomy for papillary or follicular thyroid carcinoma may be performed using diagnostic imaging with either 123I or 131I. The former is often preferred to avoid ‘‘stunning’’—defined as a reduction in uptake of the therapeutic dose of 131I caused by some form of cell damage from the diagnostic dosage of the radionuclide. Stunning could potentially reduce ...